Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom
Author(s)
Chris Raspin, MSc1, Coline Dubois de Gennes, PharmD1, Yasmeeta Vekria, BSc (Hons)1, Marie Libérée Nishimwe, MSc2, Claire O'Reilly, MPharm1, Susan Farrow, BM BCh, MA1, Abda Mahmood, BSc (Hons), MSc, PhD3.
1GSK, London, United Kingdom, 2GSK, Rueil Malmaison, France, 3GSK, Wavre, Belgium.
1GSK, London, United Kingdom, 2GSK, Rueil Malmaison, France, 3GSK, Wavre, Belgium.
OBJECTIVES: Herpes zoster (HZ) results from the reactivation of latent varicella zoster virus, acquired previously in life. The risk of post-herpetic neuralgia (PHN), the most frequent HZ complication, increases in adults with immunocompromising (IC) conditions. In 2024, the Joint Committee on Vaccination and Immunisation extended its recommendation of the recombinant zoster vaccine (RZV), for inclusion in the United Kingdom (UK) National Immunisation Programme, from severely immunocompromised adults aged ≥50 years to severely immunocompromised adults aged ≥18 years. In this abstract, we evaluate the potential public health impact of RZV introduction in adults aged 18-49 years with at least one of five IC conditions: haematological malignancies (HM), haematopoietic stem cell transplantation (HSCT), human immunodeficiency virus (HIV), solid organ transplant (SOT), and solid organ malignancy (SOM).
METHODS: The ZOster ecoNomic Analysis (ZONA) model was adapted to the UK setting using primarily HZ and PHN incidence and IC condition prevalence data from the UK Clinical Practice Research Datalink (2012-2019) to assess RZV public health impact. For each IC condition, outcomes in a hypothetical non-vaccinated cohort were compared to those vaccinated over a 30-year period. Outcomes included HZ cases, PHN cases, hospitalisations and general practitioner (GP) visits.
RESULTS: For the HM, HSCT, HIV, SOT, SOM populations aged 18-49 years, the number of HZ cases avoided over the modelled 30-year time horizon were 1,856, 164, 3,231, 1,539, 10,615, and the number of PHN cases avoided were 368, 40, 637, 319, 2,496, respectively. Corresponding reductions in GP visits and hospitalisations were 2,422, 269, 4,216, 2,008, 28,473, and 174, 14, 304, 145, 973, respectively. The number needed to vaccinate to prevent one HZ case was 28/18/15/17/23 across the same populations.
CONCLUSIONS: Vaccination with RZV could significantly reduce the HZ-related burden in adults aged 18-49 years living with an IC condition in the UK.
METHODS: The ZOster ecoNomic Analysis (ZONA) model was adapted to the UK setting using primarily HZ and PHN incidence and IC condition prevalence data from the UK Clinical Practice Research Datalink (2012-2019) to assess RZV public health impact. For each IC condition, outcomes in a hypothetical non-vaccinated cohort were compared to those vaccinated over a 30-year period. Outcomes included HZ cases, PHN cases, hospitalisations and general practitioner (GP) visits.
RESULTS: For the HM, HSCT, HIV, SOT, SOM populations aged 18-49 years, the number of HZ cases avoided over the modelled 30-year time horizon were 1,856, 164, 3,231, 1,539, 10,615, and the number of PHN cases avoided were 368, 40, 637, 319, 2,496, respectively. Corresponding reductions in GP visits and hospitalisations were 2,422, 269, 4,216, 2,008, 28,473, and 174, 14, 304, 145, 973, respectively. The number needed to vaccinate to prevent one HZ case was 28/18/15/17/23 across the same populations.
CONCLUSIONS: Vaccination with RZV could significantly reduce the HZ-related burden in adults aged 18-49 years living with an IC condition in the UK.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH199
Topic
Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines